Lilly slightly lowers self-pay prices for single-dose vials of Zepbound
Eli Lilly will shave $50 off the self-pay price for most single-dose vials of its blockbuster weight loss drug Zepbound, about a month after agreeing to lower the prices for its multi-dose pens as part …
WHO Guideline on GLP-1 Therapies for Obesity in Adults
This Special Communication summarizes the WHO guideline on the management of obesity with GLP-1 therapies in adults and calls on nations to ensure equitable access to obesity prevention and management interventions.
WHO warning over shortage of obesity jabs – BBC
WHO warning over shortage of obesity jabs BBC WHO recommends GLP-1 drugs for obesity NBC News World Health Organization issues first-ever guidelines for use of GLP-1 weight loss medications ABC News WHO says weight loss drugs are ‘new chapter’ in fight against obesity The Guardian World Health Organization recommends GLP-1s for obesity. There’s a catch. USA Today
Popular fat jab could slow Alzheimer’s by slashing brain shrinkage and boosting memory
A FAT jab could help slow down Alzheimer’s by slashing brain shrinkage, according to a small British study. Liraglutide, the GLP-1 drug already used to manage type 2 diabetes, has sparked fresh hope that weight-loss injections could protect the brain. It comes just days after semaglutide, the ingredient in blockbuster jab Wegovy, was found not to…
WHO recommends Ozempic-style weight loss drugs for obesity
Obesity affects more than 1 billion people worldwide and is recognized by the World Health Organization as a chronic, relapsing disease associated with substantial morbidity, mortality, and economic burden.
WHO backs GLP-1 treatments to tackle obesity epidemic
The World Health Organization has unveiled new recommendations indicating that revolutionary weight-loss drugs could play a vital role in addressing the escalating obesity epidemic. Specifically, GLP-1 agonist therapies are suggested for long-term obesity care in adults.
WHO recommends use of GLP-1 drugs for obesity
WHO recommends use of GLP-1 drugs for obesity
WHO conditionally recommends GLP-1 drugs for obesity
The first conditional recommendation by the organization advises the use of GLP-1 drugs by adults, except pregnant women, for long-term obesity treatment, while the second suggests interventions like a healthy diet and physical activity to be offered alongside the medicines.
GLP-1 Medications Just Got WHO’s Backing — Here’s The Part You Can’t Ignore
A global green light for GLP-1s—and a reminder to keep lifting heavy.
Why the Marks & Spencer share price fell 14% in November
November proved to be a tough month for the Marks & Spencer (LSE:MKS) share price. It was one of the worst-performing stocks in the FTSE 100, falling almost 14% in the month. Here’s what caused the move and where I think it could go from here. Key factors to note In April 2025, the business […]